Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypercholesterolemia AND Dyslipidemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Hypercholesterolemia AND Dyslipidemia. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2017-003170-13 Sponsor Protocol Number: R1500-CL-1719 Start Date*: 2018-03-15
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia
    Medical condition: Homozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) NO (Prematurely Ended) CZ (Completed) FR (Completed) GR (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005747-29 Sponsor Protocol Number: BP20843 Start Date*: 2007-03-14
    Sponsor Name:F. HOFFMANN-LA ROCHE LTD
    Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs
    Medical condition: Primary hypercholesterolemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001000-39 Sponsor Protocol Number: NK-104-301 Start Date*: 2006-05-04
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: STUDY OF PITAVASTATIN 2 MG vs. ATORVASTATIN 10 MG AND PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Medical condition: Primary Hypercholesterolemia or Combined Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.1 10020604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003189-16 Sponsor Protocol Number: R727-CL-1532 Start Date*: 2016-12-22
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial H...
    Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia with High and Very High Cardiovascular Risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10054380 Familial hypercholesterolemia LLT
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.0 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001039-31 Sponsor Protocol Number: NK-104-306 Start Date*: 2005-08-11
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: STUDY OF PITAVASTATIN 1 MG vs. PRAVASTATIN 10 MG, PITAVASTATIN 2 MG vs. PRAVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. PRAVASTATIN 40 MG (FOLLOWING UP-TITRATION) IN ELDERLY PATIENTS WITH PRIMARY HYPER...
    Medical condition: PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Disease: Version SOC Term Classification Code Term Level
    7.1 10020604 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005093-70 Sponsor Protocol Number: 0524A-020 Start Date*: 2005-12-29
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercho...
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10020603 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) AT (Completed) DE (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001489-34 Sponsor Protocol Number: TAK-475_306 Start Date*: 2007-10-01
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd
    Full Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension
    Medical condition: Subjects With Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Completed) EE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) NL (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001112-41 Sponsor Protocol Number: NK-104-307 Start Date*: 2006-06-26
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: OPEN-LABEL, LONG TERM (1 YEAR) EXTENSION STUDY OF PITAVASTATIN 4MG QD IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA
    Medical condition: Patients with hypercholestrolemia or combined dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003236-37 Sponsor Protocol Number: 20160184 Start Date*: 2018-11-02
    Sponsor Name:Amgen Inc.
    Full Title: High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001931-30 Sponsor Protocol Number: R1500-CL-17100 Start Date*: 2020-08-17
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia
    Medical condition: Homozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003626-26 Sponsor Protocol Number: 01-05-TL-475-016 Start Date*: 2006-06-14
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous f...
    Medical condition: Treatment of primary dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001388-19 Sponsor Protocol Number: R1500-CL-1629 Start Date*: 2018-06-18
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia
    Medical condition: Homozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) AT (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004876-19 Sponsor Protocol Number: 01-05-TL-475-021 Start Date*: 2006-02-13
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia
    Medical condition: Treatment of patients with primary hypercholesterolemia currently taking atorvastatin (80mg), simvastatin (80mg) or rosuvastatin (40mg)
    Disease: Version SOC Term Classification Code Term Level
    8 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) SE (Prematurely Ended) NO (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001364-30 Sponsor Protocol Number: 20110116 Start Date*: 2012-09-07
    Sponsor Name:Amgen Inc
    Full Title: Title: A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a ...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020604 Hypercholesterolemia LLT
    14.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DK (Completed) NL (Completed) PL (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000465-37 Sponsor Protocol Number: 0524A-082 Start Date*: 2008-05-30
    Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Ther...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005272-19 Sponsor Protocol Number: 20190184 Start Date*: 2023-01-08
    Sponsor Name:Amgen Inc
    Full Title: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000166-33 Sponsor Protocol Number: SLICK-001 Start Date*: 2023-04-12
    Sponsor Name:Semmelweis University
    Full Title: Implementation study of lipid management of high-risk cardiovascular patients- Semmelweis Lipid Center for high-risk patients
    Medical condition: primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    20.0 100000004850 10054380 Familial hypercholesterolemia LLT
    20.0 100000004850 10077966 Primary hypercholesterolemia LLT
    21.0 100000004861 10058110 Dyslipidemia LLT
    20.1 100000004861 10079969 Atherogenic dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004413-33 Sponsor Protocol Number: KBT-004 Start Date*: 2007-10-26
    Sponsor Name:Karo Bio AB
    Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipid...
    Medical condition: Primary hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020603 Hypercholesterolaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-002853-77 Sponsor Protocol Number: TULIP Start Date*: 2011-10-20
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: PROSPECTIVE, RANDOMISED, CROSSOVER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE LIPID-LOWERING EFFECT OF ADDING TENOFOVIR/EMTRICITABINE CO-FORMULATION VS PLACEBO TO HIV-1-INFECTED SUBJECTS...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002911-80 Sponsor Protocol Number: LOCHNES Start Date*: 2018-12-18
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO "PAOLO GIACCONE" DI PALERMO
    Full Title: Open-label study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome
    Medical condition: Familial Chylomicronemia Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 08:47:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA